Pfizer's strong Q3 earnings and upgraded 2024 guidance indicate improving fundamentals. The strategic focus on the oncology market, which is fast-growing, enhances future revenue prospects. The stock is currently undervalued, with a 32% upside potential based on intrinsic value calculations. Additionally, the forward dividend yield is attractive, supported by revenue growth and R&D investments, making the stock appealing to investors.